Spectinomycin
Spectinomycin is an aminocyclitol antibiotic with a mechanism similar to aminoglycosides, inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit and interfering with mRNA translocation, used primarily as an alternative treatment for uncomplicated gonorrhea in patients who cannot tolerate cephalosporins or fluoroquinolones. Unlike aminoglycosides, it is not nephrotoxic or ototoxic at therapeutic doses. Its investigational use in stroke is based on potential neuroprotective properties unrelated to its antibiotic activity.
Molecular Weight
332.3500 g/mol
LogP
-3.10
TPSA
130.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
2D Structure
Cite this structure
Embed this structure
SMILES
CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O
InChI
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
Molecular Formula
C14H24N2O7
HBD / HBA
5 / 9
Rotatable Bonds
2
Heavy Atoms
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Spectinomycin is an aminocyclitol antibiotic with a mechanism similar to aminoglycosides, inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit and interfering with mRNA translocation, used primarily as an alternative treatment for uncomplicated gonorrhea in patients who cannot tolerate cephalosporins or fluoroquinolones. Unlike aminoglycosides, it is not nephrotoxic or ototoxic at therapeutic doses. Its investigational use in stroke is based on potential neuroprotective properties unrelated to its antibiotic activity.
Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.
Yes, Spectinomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1167. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 15541. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="spectinomycin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/spectinomycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/spectinomycin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/spectinomycin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="spectinomycin"></drugfyi-drug>